---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-009743"
form_type: "8-K"
ticker: "PTN"
cik: "0000911216"
company_name: "PALATIN TECHNOLOGIES INC"
filed_at: "2025-08-18T23:59:59+00:00"
generated_at: "2026-05-17T12:16:17.234715+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Palatin signs up to €280M collaboration with Boehringer for retinal disease therapies

## Summary
- €2M upfront, up to €18M near-term milestones, up to €260M in regulatory/commercial milestones plus tiered royalties.
- Collaboration focuses on melanocortin receptor agonists for diabetic retinopathy and DME; Boehringer funds two-year research.
- Palatin assigned patent rights to Boehringer; potential first-in-class treatment targeting inflammation, vascular dysfunction, neurodegeneration.

## SEC filing metadata
- accession: 0001654954-25-009743
- form_type: 8-K
- ticker: PTN
- cik: 0000911216
- company_name: PALATIN TECHNOLOGIES INC
- filed_at: 2025-08-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/911216/000165495425009743/0001654954-25-009743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/911216/000165495425009743/ptn_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-009743
- JSON: https://secwatch.observer/filing/0001654954-25-009743.json
- Plain text: https://secwatch.observer/filing/0001654954-25-009743.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.